AIkido Pharma Inc Stock

$4.99

4.39% yesterday

Nasdaq, Jul 11, 10:09 pm CET

ISIN

US0088751062

Symbol

DOMH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

AIkido Pharma Inc Stock price

$4.99

-8.86 63.98% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+0.21 4.39%

ISIN

US0088751062

Symbol

DOMH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$73.1m

Enterprise Value

$54.2m

Net debt

positive

Cash

$18.9m

Shares outstanding

14.6m

Valuation (TTM | estimate)

P/E

negative | -

P/S

2.9 | -

EV/Sales

2.2 | -

EV/FCF

negative

P/B

1.7

Financial Health

Equity Ratio

84.6%

Return on Equity

-36.9%

ROCE

-88.0%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$24.9m | -

EBITDA

$-40.6m | -

EBIT

$-40.7m | -

Net Income

$-41.8m | -

Free Cash Flow

$-5.3m

Growth (TTM | estimate)

Revenue

632.1% | -

EBITDA

-96.7% | -

EBIT

-96.2% | -

Net Income

-70.0% | -

Free Cash Flow

80.3%

EPS

$-3.9

FCF per Share

$-0.4

Short interest

4.4%

Employees

Rev per Employee

$630.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

AIkido Pharma Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a AIkido Pharma Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a AIkido Pharma Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from AIkido Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	25 25	632% 632% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	66 66	171% 171% 264%
- Research and Development Expense	- -	- -
EBITDA	-41 -41	97% 97% -163%
- Depreciation and Amortization	0.11 0.11	10% 10% 0%
EBIT (Operating Income) EBIT	-41 -41	96% 96% -164%
Net Profit	-42 -42	70% 70% -168%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

AIkido Pharma Inc Stock News

Neutral

PRNewsWire

●

25 days ago

Dominari Securities Serves as Exclusive Placement Agent to SRM Entertainment on a $100 Million Equity Investment

- SRM Launches TRON Treasury Strategy NEW YORK , June 17, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) today announced that its wholly owned subsidiary, Dominari Securities LLC, served as the exclusive placement agent, successfully leading the placement of a $100 million equity investment for SRM Entertainment, Inc. (Nasdaq: SRM). The transaction, which included the issuance of 1...

Neutral

PRNewsWire

●

about one month ago

Dominari Holdings Set to Join Russell Microcap® Index

NEW YORK , May 28, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH), is set to join the Russell Microcap® Index at the conclusion of the 2025 Russell indexes annual reconstitution, effective after the US market opens on June 30, according to a preliminary list of additions posted May 23. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday,...

Neutral

PRNewsWire

●

about 2 months ago

Dominari Holding's Strategic Interest in Bitcoin Mining Set to Go Public

American Bitcoin Enters into Definitive Merger Agreement with Nasdaq-listed Gryphon Digital Mining to Build World's Largest, Most Efficient Pure-Play Bitcoin Minor Alongside A Robust and Strategic Bitcoin Reserve NEW YORK , May 13, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH), today congratulates American Bitcoin on entering into a definitive merger agreement with Gryphon Digital ...

More AIkido Pharma Inc News

Company Profile

Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.

Head office	United States
CEO	Anthony Hayes
Employees	29
Founded	1967
Website	www.dominariholdings.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now